

ACCELERATED ACCESS COLLABORATIVE

NICE UPDATE ON THE INNOVATIVE LICENSING AND ACCESS PATHWAY

Executive summary

- NICE's new 5-year strategy has a strong focus on rapid, robust and responsive evaluation of new and emerging technologies and NICE's involvement in the Innovative Licensing and Access Pathway (ILAP) is a great example of this.
- NICE has been working closely with the Medicines and Healthcare Regulation Authority (MHRA) and other partners to develop and establish processes to support the implementation of the ILAP. This work is further enhancing the good collaborative working relationships established via other initiatives such as RAPID C-19.
- This paper provides an update on progress with this ongoing work.

Board members are asked to:

- Note the update on progress on delivery of the ILAP
- Paper to note, members to email their comments to aac.innovation@nhs.net by 7 July.

Background

1. The ILAP was launched in January 2021 and aims to accelerate the time to market, facilitating safe, early and financially sustainable patient access to medicines. NICE is a permanent partner in the ILAP.
2. In [NICE's new 5-year strategy](#), we set out our strategic vision to be at the forefront of anticipating and evaluating new and emerging health technologies to provide independent, world leading assessment of value to the system and improved access for patients. NICE's involvement in the ILAP is a great example of this.
3. NICE has been working closely with the MHRA, Scottish Medicines Consortium (SMC) and other partners in the design of ILAP, to support delivery and to ensure that NICE is fully aligned, appropriately informed and resourced to deliver on its commitments.

Progress on delivering the ILAP

4. NICE is fully engaged in work with the MHRA and SMC to support the development of ILAP processes. NICE has senior participation in the ILAP steering group and multiple members of staff are embedded in ongoing joint strategic ILAP work packages with MHRA and SMC colleagues. These work packages are focussed on development of the range of innovative and flexible activities which NICE will offer as an ILAP partner, which include scientific

advice, enhanced patient engagement, and other areas which underpin delivery of the ILAP such as funding and resources and communications.

5. The NICE Life Sciences Team has established the operational interface with the ILAP and has been working with the MHRA to develop operational processes between the two organisations and to implement operational processes within NICE.
6. After some initial challenges, good progress has been made on sharing of key information to enable NICE to coordinate activity, and plan and resource its work programmes to deliver on its ILAP commitments. This includes timely sharing of information around key milestones within the ILAP processes to enable effective and timely engagement from NICE, and information to enable systematic tracking and scheduling of ILAP products.
7. The Life Sciences Team is also working with the MHRA on activity forecasting for 2021 and future years. This forecasting will help ensure that teams within NICE which will contribute to the range of innovative and flexible support activities offered via the ILAP are able to effectively plan and schedule additional activity into their work programmes and that they are appropriately resourced to deliver any extra work.
8. We have established strategic and operational touchpoints with MHRA colleagues through this work, which is further enhancing the collaborative working relationships established via other initiatives such as RAPID C-19.
9. NICE is in active communication with companies which are confirmed or potentially included in Project ORBIS to proactively plan scheduling into NICEs technology appraisal programmes.
10. NICE has initiated development of a communications strategy to support the ILAP and has published a [blog](#) highlighting the exciting developments and opportunities which are involved.

Board members are asked to:

- Note the update on progress on delivery of the ILAP
- Paper to note, members to email their comments to aac.innovation@nhs.net by 7 July.

Authors:

Carla Deakin, Programme Director Commercial and Managed Access, NICE

Chris Feinmann, Programme Manager, Life Sciences Team. NICE